Market Size (2016)
2016
$1.27B
Healthcare
Myasthenia Gravis Market
By Segment, By Region, And Segment Forecasts, 2016 – 2027
Vertical: HealthcareBase Year: 201912 Sections
Executive Summary
Myasthenia Gravis Market — Snapshot
Projected (2027)
2027
$3.11B
CAGR (2016–2027)
8.5%
8.5%Key Players
105+
Acquired myasthenia gravis (MG) is a neuromuscular disease caused by autoantibodies against components of the neuromuscular junction Patients suffer from fluctuating, fatigable muscle weakness that worsens with activity and improves with rest.
The key factors that drive the myasthenia gravis market are the rising research funding for myasthenia gravis, awareness programs and initiatives taken by associations, and rising prevalence of myasthenia gravis. However, the high cost of treatment associated with myasthenia gravis hamper market growth
Key Insight
The Myasthenia Gravis Market market is projected to grow at a CAGR of 8.5% from 2016 to 2027.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: Europe, Asia Pacific, Middle East and Africa, Americas.
- Market Segmentation: The market is analyzed across 4 segments: Ocular Myasthenia Gravis, Generalized Myasthenia Gravis, Congenital Myasthenia Gravis, Type_Others. Forecasts are provided for each segment from 2016 to 2027.
- Competitive Landscape: 105 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Myasthenia Gravis Market — Growth Trajectory
Myasthenia gravis (MG) is a neuromuscular disorder primarily characterized by muscle weakness and muscle fatigue. Although the disorder usually becomes apparent during adulthood, symptom onset may occur at any age. At present, research is focused on a better understanding of the specifics of the autoimmune problems associated with MG and improving their diagnosis and treatment. Furthermore, the market is observing a paradigm shift in the area of research from suppressing the immune system to rebalancing it.
Myasthenia Gravis Market — Growth Trajectory
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Type Type is broken down into: Ocular Myasthenia Gravis, Generalized Myasthenia Gravis, Congenital Myasthenia Gravis, Type_Others.
- Diagnosis & Treatment Diagnosis & Treatment is broken down into: Diagnosis, Treatment.
- End User End User is broken down into: Hospitals & Clinics, Diagnostic Centers, Academic & Research Organizations.
Geographic Analysis
Regional market breakdown
- Europe Europe market size reached $423.31M in 2016 and is projected to reach $1.06B by 2027, growing at a CAGR of 8.7%.
- Asia Pacific Asia Pacific market size reached $268.49M in 2016 and is projected to reach $679.59M by 2027, growing at a CAGR of 8.8%.
- Middle East and Africa Middle East and Africa market size reached $69.85M in 2016 and is projected to reach $172.95M by 2027, growing at a CAGR of 8.6%.
- Americas Americas market size reached $507.01M in 2016 and is projected to reach $1.19B by 2027, growing at a CAGR of 8.1%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Myasthenia Gravis Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2019
Historical Period
2016 – 2019
Forecast Period
2019 – 2027
Primary Interviews
150+
Research Process
Historical data (2016–2019) and forecast period (2019–2027)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Myasthenia Gravis Market — Competitive Analysis
Threat of New Entrants
The threat of new entrants in the global myasthenia gravis market is medium. Any company trying to enter the market is required to accept the mandatory regulatory standards issued by government authorities. The market is also characterized by a high degree of brand loyalty, where establishing a brand name is difficult for newcomers. The rise in the demand for myasthenia gravis disease treatment owing to its potential growth in the coming future is expected to attract the currently established and other manufacturers to focus more on this segment. Furthermore, the cost involved in research and development (R&D) is comparatively high, which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
The bargaining power of suppliers in the myasthenia gravis market is medium to high. MG is an autoimmune neuromuscular disorder. There is only one FDA approved drug available for the treatment of myasthenia gravis. But various multinational and local companies are participating actively in launching effective drugs in the market to meet the proposed FDA guidelines. Another factor affecting the bargaining power of suppliers is the switching cost for buyers owing to the presence of local companies. Furthermore, many companies are focusing on the development of new treatment options which increases the competition in the market.
Threat of Substitutes
The threat of substitutes in the myasthenia gravis market is low. There are very few substitutes available in the market, and buyer propensity to substitute is low as most of the medical professionals prescribe a limited number of drugs. Moreover, there is only one FDA approved drug available in the market and other drugs are in the clinical phase. The substitute drugs available in the market are for symptomatic treatment.
Bargaining Power of Buyers
The bargaining power of buyers is low to medium in the myasthenia gravis market. Patients are the major buyers for the market. The presence of buyers in the market is low to medium. Myasthenia gravis is a rare disorder that had a prevalence rate of 15 to 179 per million individuals in 2017. In addition, buyers are price-sensitive, which moderately affects their bargaining power in the market. The market is characterized by a low to medium availability of substitute products which reduces the buying power in the industry.
Intensity of Rivalry
The degree of competition in the myasthenia gravis market is medium. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in myasthenia gravis market are trying to develop better and cost-effective products to make product differentiation more affordable in developing regions. To overcome the competition, players are engaged in developing a process to lower their manufacturing costs. Moreover, the players are also developing advanced techniques for differentiating their product from their rivals.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Myasthenia Gravis Market.
Regional Market Size (USD Mn)
Market estimates by geography (2027)
USD Mn
InsightAmericas leads with $1.19B by 2027, while Asia Pacific is projected to grow fastest at a 8.8% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2016 | 2019 | 2027 | CAGR | SHARE |
|---|---|---|---|---|---|
| Europe | $423.31M | $714.75M | $1.06B | 8.7% | 34% |
| Asia Pacific | $268.49M | $456.06M | $679.59M | 8.8% | 22% |
| Middle East and Africa | $69.85M | $117.23M | $172.95M | 8.6% | 6% |
| Americas | $507.01M | $828.54M | $1.19B | 8.1% | 38% |
| Total | $1.27B | $2.12B | $3.11B | 8.5% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2027)
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Congenital Myasthenia Gravis
Type_Others
034769510421389
Segment Market Share
- Ocular Myasthenia Gravis41%
- Generalized Myasthenia Gravis29%
- Congenital Myasthenia Gravis17%
- Type_Others13%
Total Market Size
$3.11B
Market by Segment (2027)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Ocular Myasthenia Gravis | $1.26B | 8.5% | 85% |
| Generalized Myasthenia Gravis | $910.45M | 8.5% | 73% |
| Congenital Myasthenia Gravis | $520.45M | 8.5% | 53% |
| Type_Others | $413.47M | 8.5% | 89% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Myasthenia Gravis Market — Key Findings
Analytical insights on Myasthenia Gravis Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Myasthenia Gravis Market market is projected to reach $3.11B by 2027, growing at 8.5% CAGR. The Ocular Myasthenia Gravis segment holds the largest share.
Market Dynamics
Acquired Myasthenia Gravis (MG) is a neuromuscular disease caused by autoantibodies against components of the neuromuscular junction.Patients suffer from fluctuating, fatigable muscle weakness that worsens with activity and improves with rest.
The global myasthenia gravis market is mainly driven by the rising research funding for myasthenia gravis, awareness programs and initiatives taken by associations, and the rising prevalence of MG. However, the high cost of treatment associated with MG may slow the growth of the market.
Market Drivers
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder. In MG, the postsynaptic muscle membrane is distorted. In MG, the fundamental defect is a decrease in the concentration of AChRs on the muscle endplate membrane. The disease occurs mostly in adults, and the typical clinical symptoms are ocular, bulbar, or generalized weakness and fatigability. Since the last three decades, increasing prevalence of MG had been reported, mainly due to late-onset MG. Owing to the rising cases of MG and related complications, various government bodies and private foundations, such as the Myasthenia Gravis Foundation of America (MGFA), the Muscular Dystrophy Association (MDA), and others, are actively participating in the improvement of research funding.
The National Institutes of Health (NIH) awarded USD 7.8 million to researchers at George Washington University to launch a network for improving research, treatment, and education in myasthenia gravis. According to the 2017 research funding agenda published by MGFA, the association has funded highly valuable projects with a maximum direct cost of USD 50,000 per year and a maximum 10% indirect cost rate.
Even in the past years, a researcher from the University of Illinois received a research grant of USD 240,000 to further explore the causes of myasthenia gravis by the American Brain Foundation and Myasthenia Gravis Foundation of America. The grant allowed the researcher to research regulatory T lymphocyte and its role in a variety of other autoimmune diseases. The three-year award consists of an annual salary of USD 75,000 plus USD 5,000 in educational expenses every year to support the scientist's research related to myasthenia gravis. Moreover, a Professor at George Washington University was awarded a Muscular Dystrophy Association (MDA) research grant of USD 367,187 over three years to test a therapeutic strategy in cell and rat models of MG, with an intent to determine the feasibility of the approach and then move to human clinical trials.
From all the information, it is observed that the escalating research funding for myasthenia gravis will boost the myasthenia gravis market.
Market Opportunities
The Food and Drug Administration (FDA) and other government bodies are establishing a new standard for MG therapeutics accuracy. The FDA standard is majorly driven by technological advances, improved meter accuracy, research studies, and consumer complaints about products. Due to increasing cases of MG, the competition among therapeutic and diagnostic manufacturers is also rising. Market players are continuously coming up with innovative products to meet the proposed FDA guidelines.
There is only one FDA approved the drug for the treatment of myasthenia gravis. However, several clinical trials are undergoing. For instance, in April 2018, Catalyst Pharmaceuticals, Inc. announced the enrollment of the first patient into its Phase 3 clinical trial to evaluate the efficacy and safety of Firdapse (amifampridine phosphate) in patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG).
In September 2018, Argenx initiated the global pivotal Phase 3 clinical trial of Efgartigimod (ARGX-113) to test efficacy in patients with generalized myasthenia gravis (gMG).
The development of these new drugs will boost the myasthenia gravis market in the near future.
Market Restraints
Myasthenia gravis is the primary disorder of neuromuscular transmission which is estimated to affect nearly 700,000 people worldwide. Owing to the increasing prevalence of MG, the treatment options are also increasing. But a single treatment approach is not best for all patients as MG is a heterogeneous condition.
The current mainstay of treatment for MG is an immunomodulation therapy which also has been a major factor in improving the prognosis for patients in recent years.
In many cases, patients require multiple therapies including immunosuppressants, cholinesterase inhibitors, plasmapheresis, and others. The cost of drugs and other treatments is very high especially for those with severe symptoms. According to the National Blood Authority, nearly 6 to 7% of IVIG is issued nationally for patients with MG which costs around USD10 million annually. A study published in 2017 also reported that the total cost for MG rose13-folds from 2003 to 2013.
Soliris (Eculizumab) is the FDA approved a drug used for the treatment of patients with generalized myasthenia gravis (gMG). It is found that, as of 2017, the wholesale acquisition cost (WAC) of Soliris was USD 6,522.90 for a 300 mg vial and a total WAC 900 mg dose was USD 19,569. So, the total monthly cost of Soliris comes around USD 521,832, i.e., USD 0.52 per member per month (PMPM). This represents a significant amount of spend for a small population.
From all the information, it can be concluded that the high cost of treatment associated with myasthenia gravis can strongly impact the growth of the market.
Strategic Outlook and Future Directions
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Market Value by Segment (2027)
Value (USD Mn)
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Congenital Myasthenia Gravis
Type_Others
Companies
Key companies profiled in Myasthenia Gravis Market
Profiles of 105 companies operating in the Myasthenia Gravis Market market, including revenue, employee count, and market positioning where available.
Showing 105 of 105 companies
CSL Behrin
CSL Behring
Healthcare
Company Headquarters: USA Founded: 2000 Workforce: ~27,000 Revenue: USD 10.56 Billion (December 31, 2021) Company Working: CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia; hereditary angioedema; inherited respiratory disease; and neurological disorders. CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. Company collaborates with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research. CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity, and superior performance. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries. CSL Limited is the parent company of global biotechnology leader CSL Behring; the world's largest collector of human plasma, CSL Plasma; and global leader in influenza prevention, Seqirus. CSL Limited is based in Melbourne, Victoria, Australia, and is traded on the Australian Securities Exchange (ASX) under the symbol CSL.
Revenue$6.9B
Employees27,000
Market CapN/A
Founded1999
USA
Takeda Pha
Takeda Pharmaceutical Company Limited
Healthcare
Company Headquarters: Japan Founded: 1925 Workforce: ~ 47,347 Company Working: Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs, and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases, and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Revenue$30.3B
Employees47,347
Market CapN/A
Founded1924
Japan
Baxter Int
Baxter International
Healthcare
Company Headquarters: Deerfield, Illinois, US Founded: 1931 Workforce: ~50,000 Company Working: Baxter International Inc. (Baxter) is a Fortune 500 American health care company with headquarters in Deerfield, Illinois, US. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. Baxter is a leading producer of intravenous (IV) fluids and systems. It also manufactures infusion pumps, pre-filled syringes, biological sealants, and inhaled anesthetics, as well as dialyzers and other products for the treatment of end-stage renal disease. Its global footprint and critical nature of products and services play a key role in expanding access to healthcare in emerging and developed countries. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. As of December 31, 2018, Baxter manufactured products in over 20 countries and sold them in over 100 countries.
Revenue$10.2B
Employees50,000
Market CapN/A
Founded1930
Deerfield, Illinois, US
Novartis A
Novartis AG.
Healthcare
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: 1, 26,000 Company Working: Novartis AG was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis AG and its predecessor companies have a rich history of developing innovative new products that trace back to more than 250 years. The company focuses on the development and marketing of new products that contribute to human progress through advances in science and health. It provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardio-metabolic, and established medicine products.
Revenue$42.3B
Employees26,000
Market CapN/A
Founded1995
Basel, Switzerland
F. HOFFMAN
F. HOFFMANN-LA ROCHE LTD
Healthcare
Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.
Revenue$63.3B
EmployeesN/A
Market CapN/A
FoundedN/A
United States, North America
Novavax, I
Novavax, Inc.
Healthcare
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Revenue$0.5B
Employees2,500
Market CapN/A
Founded1986
Maryland, US
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Myasthenia Gravis Market
Starting from
$4,950